Viewing Study NCT01186861

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:38 PM
Ignite Modification Date: 2026-02-02 @ 12:37 PM
Study NCT ID: NCT01186861
Status: COMPLETED
Last Update Posted: 2025-11-18
First Post: 2010-08-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Sponsor: Astellas Pharma Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles … View
Keywords:

Keywords

Keyword Brief Keyword Text View
None OSI-906 View
None Erlotinib View
None Platinum-based chemotherapy View
None Placebo View
None NSCLC View